中国实用医刊
中國實用醫刊
중국실용의간
CENTRAL PLAINS MEDICAL JOURNAL
2013年
9期
37-38
,共2页
RHO激酶抑制剂%心衰%心室重构%基质金属蛋白酶2%转化生长因子-β1
RHO激酶抑製劑%心衰%心室重構%基質金屬蛋白酶2%轉化生長因子-β1
RHO격매억제제%심쇠%심실중구%기질금속단백매2%전화생장인자-β1
RHO kinase inhibitors%Heart failure%Ventricular remodeling%Matrix metalloproteinases 2%Transformation growth factor-β1
目的 观察法舒地尔对慢性心力衰竭患者血浆基质金属蛋白酶(MMP-2)及转化生长因子-β1(TGF-β1)表达水平的影响,探讨RHO激酶抑制剂对心室重构的阻抑作用机制.方法 40例纽约心脏病协会(NYHA)心功能Ⅳ级患者随机分成常规治疗组和法舒地尔组.常规治疗组按照美国心力衰竭指南给予正规抗心力衰竭治疗,法舒地尔组在常规治疗基础上加用法舒地尔60 mg/d,连续应用2周.比较治疗前后左室舒张末期内径(LVEDD)、左室射血分数(LVEF)、血浆MMP-2及TGF-β1水平.结果 治疗2周后,两组的LVEDD均明显减小,LVEF明显提高(P＜0.01),血浆MMP-2以及TGF-β1水平均明显降低,且法舒地尔组优于对照组(P＜0.05).结论 慢性心力衰竭患者发生左室重构,心脏收缩功能下降,血浆MMP-2和TGF-β1表达增多,提示两者可能参与了心衰心室重构的发生发展过程,而法舒地尔能下调MMP-2和TGF-β1的表达水平,提示法舒地尔可能通过此途径发挥改善心衰心室重构的作用.
目的 觀察法舒地爾對慢性心力衰竭患者血漿基質金屬蛋白酶(MMP-2)及轉化生長因子-β1(TGF-β1)錶達水平的影響,探討RHO激酶抑製劑對心室重構的阻抑作用機製.方法 40例紐約心髒病協會(NYHA)心功能Ⅳ級患者隨機分成常規治療組和法舒地爾組.常規治療組按照美國心力衰竭指南給予正規抗心力衰竭治療,法舒地爾組在常規治療基礎上加用法舒地爾60 mg/d,連續應用2週.比較治療前後左室舒張末期內徑(LVEDD)、左室射血分數(LVEF)、血漿MMP-2及TGF-β1水平.結果 治療2週後,兩組的LVEDD均明顯減小,LVEF明顯提高(P＜0.01),血漿MMP-2以及TGF-β1水平均明顯降低,且法舒地爾組優于對照組(P＜0.05).結論 慢性心力衰竭患者髮生左室重構,心髒收縮功能下降,血漿MMP-2和TGF-β1錶達增多,提示兩者可能參與瞭心衰心室重構的髮生髮展過程,而法舒地爾能下調MMP-2和TGF-β1的錶達水平,提示法舒地爾可能通過此途徑髮揮改善心衰心室重構的作用.
목적 관찰법서지이대만성심력쇠갈환자혈장기질금속단백매(MMP-2)급전화생장인자-β1(TGF-β1)표체수평적영향,탐토RHO격매억제제대심실중구적조억작용궤제.방법 40례뉴약심장병협회(NYHA)심공능Ⅳ급환자수궤분성상규치료조화법서지이조.상규치료조안조미국심력쇠갈지남급여정규항심력쇠갈치료,법서지이조재상규치료기출상가용법서지이60 mg/d,련속응용2주.비교치료전후좌실서장말기내경(LVEDD)、좌실사혈분수(LVEF)、혈장MMP-2급TGF-β1수평.결과 치료2주후,량조적LVEDD균명현감소,LVEF명현제고(P＜0.01),혈장MMP-2이급TGF-β1수평균명현강저,차법서지이조우우대조조(P＜0.05).결론 만성심력쇠갈환자발생좌실중구,심장수축공능하강,혈장MMP-2화TGF-β1표체증다,제시량자가능삼여료심쇠심실중구적발생발전과정,이법서지이능하조MMP-2화TGF-β1적표체수평,제시법서지이가능통과차도경발휘개선심쇠심실중구적작용.
Objective To observe the effects of fasudil on levels of plasma MMP-2 and TGF-β1 in patients with chronic heart failure,and investigate the resistance mechanism of RHO kinase inhibitors in the process of ventricular remodeling.Methods Fourty patients with New York Heart Association (NYHA) NYHA Ⅳ were randomly divided into conventional treatment group and fasudil grou.Patients in conventional treatment group were given a formal anti-heart failure treatment according to the American heart failure guidelines,patients in fasudil group additionally received fasudil 60 mg dose intravenous drip qd for two weeks.The levels of plasma MMP-2,TGF-β1,LVEDD,LVEF were measured and compared before and after the treatment between the two groups.Results The MMP-2 and TGF-β1 plasma levels in the two groups decreased significantly after 2 weeks treatment (P ＜ 0.01),and fasudil treatment group was more obvious than conventional treatment group (P ＜ 0.05).Conclusions The patients with chronic heart failure with ventricular remodeled,heart contraction function droped,the MMP-2 and TGF-β1 expression levels increased,both may be involved in the heart failure of ventricular remodeling process.Fasudil can decrease MMP-2 and TGF-β1 expression levels,indicating that fasudil may play the role of ventricular remodeling in heart failure through this way.
